Integrated network pharmacology, molecular docking, and experimental validation to reveal the potential mechanism of Ginsenoside Rg1 on chronic obstructive pulmonary disease Authors: Xinpeng Li, Dandan Xiang, Lingling Hu, Lingdan Lin, Guoqiang Wang, Jing Xu Published: 2026 ABSTRACT AbstractGinsenoside Rg1 (GS Rg1), a natural flavonoid exhibiting anti-inflammatory and antioxidant properties, holds significant potential for treatment chronic obstructive pulmonary disease (COPD). Nevertheless, the precise mechanisms underlying its therapeutic effects remain to be fully elucidated. This study aimed to explore the role and potential mechanism of GS Rg1 in the treatment of COPD using network pharmacology, molecular docking, and experimental validation.Targets related to GS Rg1 and COPD were screened from public databases, and the potential common targets were then imported into the STRING database to construct a protein-protein interaction (PPI) network. Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis were performed to identify key signaling pathways. Molecular docking was employed to predict the binding interactions between GS Rg1 and core targets. A BEAS-2B cell model induced by lipopolysaccharide(LPS) and cigarette smoke extract(CSE) was used to explore the protective mechanisms of GS Rg1. Western blot analysis was conducted to validate the critical targets and pathways involved in the anti-COPD effects of GS Rg1. Network pharmacology analysis revealed 105 common targets between GS Rg1 and COPD. The EGFR/PI3K/AKT and EGFR/STAT3 signaling pathways were selected for further validation. GS Rg1 was demonstrated to effectively inhibit inflammation and mucus hypersecretion in vitro models of COPD. Western blot results showed that GS Rg1 treatment significantly downregulated the expression of proteins involved in the EGFR/PI3K/AKT and EGFR/STAT3 signaling pathway, consistent with the network pharmacology findings. CSE/LPS exposure induces inflammation and oxidative stress in COPD by disrupting the EGFR/PI3K/AKT and EGFR/STAT3 signaling pathways, and GS Rg1 significantly alleviates these effects, which may be partially through regulating the EGFR/PI3K/AKT and EGFR/STAT3 signaling pathway.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1038/s41598-026-63671-0.Keywords: Chronic obstructive pulmonary disease, Ginsenoside Rg1, EGFR/PI3K/AKT signaling pathway, Molecular docking, Network pharmacologySubject terms: Computational biology and bioinformatics, Diseases, Drug discovery Introduction Chronic obstructive pulmonary disease (COPD) is a heterogeneous pulmonary disorder characterized by persistent chronic airway inflammation and structural damage to the respiratory tract1–3. It frequently progresses to pulmonary heart disease and respiratory failure, ultimately leading to death2. In recent years, various pharmacological agents, including inhaled corticosteroids, β2-adrenergic receptor agonists, muscarinic antagonists, and selective phosphodiesterase-4 (PDE4) inhibitors, have been employed in the management of COPD4,5. Nevertheless, these drugs-particularly inhaled corticosteroids, also exhibit significant side effects, such as increased risk of infection6, which significantly limits their clinical utility. Epidemiological data indicate that approximately 10% of adults are affected by COPD, which has become the third leading cause of mortality worldwide1. Considering its high prevalence, rising incidence, and high mortality rate, as well as personal, social and economic burden, COPD has been considered as a global public health issue1. Moreover, the heterogeneity of COPD pathophysiology-including persistent airway inflammation, oxidative stress, protease-antiprotease imbalance, and airway remodeling-remains inadequately addressed by existing single-target agents. Consequently, there is an urgent unmet clinical need for novel therapeutic strategies that can simultaneously modulate multiple pathogenic pathways with favorable safety profiles. Natural medicines have attracted increasing attention attributed to their fewer side effects and favorable safety profiles. Ginseng, a well-known herbal remedy, has long been recognized for its health-promoting properties7. Ginsenoside Rg1, one of the primary active components derived from ginseng, exhibits anti-inflammatory, antioxidant, and anticancer activities, and is widely used in clinical practice8. Accumulating evidence has demonstrated that GS Rg1 inhibits inflammatory responses and ameliorates hypoxia-induced pulmonary hypertension9–11. Moreover, GS Rg1 has been shown to alleviate endoplasmic reticulum stress (ERS) and improve lung injury by upregulating SIRT1 expression and modulating inflammatory processes12. Despite these well-documented pharmacological effects, the role of GS Rg1 in cigarette smoke (CS)-induced COPD remains poorly understood. In contemporary research, the mechanisms underlying pharmacological treatments for COPD are primarily explored through the establishment of disease models13. To date, several reliable modeling methods have been developed, including combined exposure to cigarette smoke and lipopolysaccharide (LPS), cigarette smoke exposure alone14, and cigarette smoke combined with protease instillation15. LPS, commonly known as endotoxin, is a component of the outer membrane of Gram-negative bacteria16 and acts as a microbial stimulus that triggers inflammatory responses17. It is hypothesized that LPS may mudulate pulmonary inflammatory and immune responses, thereby contributing to the initiation or progression of COPD18,19. The cigarette smoke extract (CSE) and lipopolysaccharide (LPS) co-stimulation model in BEAS-2B human bronchial epithelial cells has been widely employed as a relevant in vitro surrogate for COPD pathophysiology. CSE mimics the oxidative and inflammatory stress induced by cigarette smoke-the primary risk factor for COPD-while LPS, a component of Gram-negative bacterial cell walls, activates toll-like receptor 4 signaling and recapitulates the endotoxin-driven amplification of airway inflammation commonly observed during COPD exacerbations. Notably, the combined exposure to CSE and LPS better reflects that characterizes human COPD pathogenesis, including epithelial barrier disruption, neutrophil recruitment, and mucus hypersecretion. Although this model cannot fully reproduce the chronic and progressive nature of COPD in vivo, it provides a controlled, reproducible system for investigating early epithelial inflammatory and oxidative stress responses, which are critical drivers of disease initiation and progression. Therefore, to investigate the effects of potential therapeutic agents on pulmonary inflammation, we established a cellular model of COPD by exposing BEAS-2B human bronchial epithelial cells to cigarette smoke exact and LPS. Network pharmacology, an emerging paradigm in drug discovery, facilitates the identification of potential drugs-disease targets through systematic analysis of drug action networks. Given that GS Rg1 is a pleiotropic natural compound with anti-inflammatory and antioxidant activities, its therapeutic effects in COPD likely involve multiple targets and interconnected signaling pathways rather than a single molecular mechanism. Traditional experimental approaches that investigate one target or pathway at a time are inherently limited in capturing such complexity. Network pharmacology, which integrates systems biology and computational network analysis, enables systematic prediction of drug-disease interactions by constructing multi-dimensional networks of compounds, targets, and disease genes. This approach is particularly well-suited for multi-target agents like GS Rg1, as it can prioritize key nodes (e.g., hub targets and core pathways) for subsequent experimental validation. Therefore, we employed network pharmacology as a discovery-driven strategy to identify the most plausible mechanisms underlying the protective effects of GS Rg1 in COPD, followed by molecular docking to assess binding feasibility and in vitro experiments for functional confirmation. Furthermore, protein-protein interaction networks enable the prediction and evaluation of unerlying mechanisms20. Accordingly, following the research workflow depicted in Fig. 1, we integrated network pharmacology, molecular docking, and experimental validation to investigate and elucidate the potential targets and mechanisms through which GS Rg1 exerts therapeutic effects in COPD. Pharmacological analysis of the GS Rg1-COPD network. (A) Venn diagram showing the number of active targets for GS Rg1. (B) Venn diagram showing the number of targets for COPD. (C) Venn diagram illustrating the overlap between the target genes of GS Rg1 components and COPD-related genes. (D) The central 8 targets were identified as core targets based on degree values. Methods and materials Network pharmacology analysis Acquisition of GS Rg1 and COPD-Related Targets. The two-dimensional(2D) chemical structure (Figure. 2 A) and Simplified Molecular Input Line Entry System (SMILES) notation of GS Rg1 were retrieved from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/)21. The SMILES string was subsequently input into the Swiss Target Prediction platform (http://swisstargetprediction.ch)22, and only targets with a prediction probability > 0 were selected as potential effective targets of GS Rg1. Additional component-related targets were predicted by searching the HERB (https://lilab-ecust.cn/pharmmapper/) and GeneCards databases (https://www.genecards.org/)23. The results of GO and KEGG enrichment analysis. (A) GO enrichment analysis. In the first ten enrichment analysis, green, orange and purple represent the enrichment analysis of biological process, cellular component and molecular function, respectively. (B) Core genes number in each entry in KEGG pathway. (C) Bubble diagram of the top 20 pathways based on KEGG enrichment analysis. The production of these images utilized the following website information: www.kegg.jp/kegg/ kegg1. html. For the identification of COPD-related gene targets, three databases were utilized: GeneCards, MalaCards (https://www.malacards.org/), and OMIM (https://omim.org/)24. The search term “chronic obstructive pulmonary disease”was employed to identify and predict disease-associated targets. Targets obtained from all databases were merged, and duplicate entries were removed. The UniProt database (https://www.uniprot.org) was used to standardize target names into official gene symbols. Finally, the online Venn diagram tool Venny 2.1 (https://bioinfogp.cnb.csic.es/tools/venny/ index.html) was employed to construct and visualize a Venn diagram illustrating the overlapping target genes between GS Rg1 and COPD. Protein–protein interaction(PPI) network construction The intersecting targets were uploaded to the STRING database25, a protein information resource primarily used for retrieving protein sequences, predicting PPI, and visualizing such interaction networks. The biological species was set to “Homo sapiens”, the minimum interaction score threshold was adjusted to 0.4, and targets without relevant connections were hidden. The core PPI network relationship file was saved and imported into Cytoscape software (version 3.10.1)26 for visual analysis. GO and KEGG enrichment analysis The intersecting targets were submitted to the DAVID database (https://davidbioinformatics.nih.gov/) for biofunctional and pathway enrichment analysis. Pathway terms with a P-values less than 0.05 were considered statistically significant. Based on the research focus, the top 20 results were selected according to their P-values to elucidate the principal pathways and biological processes involved. Following data acquisition, the results were normalized and imported into Prism software for visualization, generating both histograms and bubble charts. Core targets The core targets in this study were analyzed and selected based on multiple factors, including topological features (degree, betweenness centrality, and closeness centrality), support from disease-related literature and databases, and pathway enrichment analysis. Molecular docking Molecular docking was performed between the main active component (GS Rg1) and the targets obtained from PPI network analysis and KEGG pathway enrichment by using the CB-Dock2 platform. This platform is a molecular docking tool based on AutoDock Vina analysis, capable of automatically identifying and analyzing ligand-receptor binding interactions.The three-dimensional (3D) chemical structure of GS Rg1 in SDF format was imported into the CB-Dock2 platform, and hydrogen atoms were individually added for free energy minimization. Concurrently, the crystal structures of the target proteins were retrieved from the RCSB Protein Data Bank (PDB) database (https://www.rcsb.org/) and then imported into the CB-Dock2 platform. During this process, hydrogen atoms were added and all water molecules were removed to prepare the proteins structures for subsequent analysis. The binding affinity energy (kcal/mol) was calculated using CB-Dock2, and the optimal docking model with the lowest binding energy was identified. Cell culture and experimental grouping BEAS-2B human bronchial epithelial cells were purchased from Beijing Beina Chuanglian Biotechnology Research Institute (BNCC100240). Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and maintained in a humidified incubator at 37℃ with 5% CO2. BEAS-2B cells were randomly divided into three groups: Control group, Model group (stimulated with 5 µg/ml LPS combined with 5% CSE for 48 h), and GS Rg1 group (stimulated with 5 µg/ml LPS combined with 5% CSE and treated with 10 µM GS Rg1 for 48 h). Following intervention with GS Rg1-medicated serum, both cells and cell culture supernatants were collected for subsequent analyses. COPD model establishment and interventions Establishment of the COPD cellular model: Based on previous studies, the COPD cell model was established through stimulation with CSE and LPS27–29. The Cell Counting Kit-8(CCK-8) assay was employed to evaluate cell viability and determine the effective concentration of GS Rg1. Subsequently, different concentrations of GS Rg1 (1, 5, 10, 20, and 50 µM) were administered to the COPD cell model according to the experimental grouping. After GS Rg1 intervention for 24 h, cells were collected for subsequent experiments. Cell counting Kit-8 (CCK-8) assay Following model establishment, BEAS-2B cells were seeded into 96-well plates at a density of 0.5 × 104 cells per well. Cells were treated with various concentrations of GS Rg1 (1, 5, 10, 20, 50µM) for 24 h. Subsequently, 10 µl of CCK-8 solution (Boster, China) was added to each well, and the plates were incubated at 37℃ for 1 h. Absorbance at 450 nm was measured using a microplate reader. Enzyme-linked immunosorbent assay (ELISA) The levels of interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) in BEAS-2B cell culture supernatants were quantitatively measured using commercially available ELISA kits (Nanjing, China). Strictly following the manufacturer’s instructions, cytokine levels were determined by measuring absorbance at a wavelength of 450 nm. Detection of MDA, SOD, CAT and ROS levels The levels of malondialdehyde (MDA), superoxide dismutase (SOD), and catalase (CAT) in BEAS-2B cells were measured using assay kits purchased from the Nanjing Jiancheng Bioengineering Institute (Nanjing, China). The supernatant of treated BEAS-2B cell cultures was discarded, and cells were resuspended in 500 µL of PBS prior to sonication. The cell lysate was centrifuged at 1000 rpm for 10 min, and the supernatant was collected for subsequent measurements. The level of reactive oxygen species (ROS) in BEAS-2B cells was quantified using a ROS detection kit (Servicebio, China). A 2′,7′- dichlorodihydro fluorescein diacetate (DCFH-DA) probe was prepared at a ratio of 1:1000 in serum-free medium. Cells were incubated with 500 µL of the DCFH-DA reagent for 30 min; following incubation, the reagent was removed, and cells were rinsed with fresh PBS. Fluorescence signals (excitation wavelength: 488 nm; emission wavelength: 525 nm) were imaged using a microscope and quantified using Image J software(version 6.0). RNA extraction and quantitative real-time PCR(RT-qPCR) Total RNA was extracted from BEAS-2B cells using an RNA extraction kit. Complementary DNA (cDNA) was synthesized from the extracted RNA using a cDNA Synthesis Kit (TaKaRa, China). RT-qPCR was performed in a 20 µL reaction volume using Ultra SYBR Mixture (CWBIO, China) on a CFX96 instrument (Tianon5200,China), following the manufacturer’s instructions for the amplification cycling protocol. The 2-ΔΔCt method was employed to analyze the RT-qPCR results. The primer sequences used were as follows: IL-6, Forward primer: AGTGAGGAACAAGCCAGAGC, Reverse primer: GGTCAGGGGTGGTTATTGCA; IL-1β, Forward primer: TGATGGCTTATTACAGTGGCAA, Reverse primer: TAGTGGTGGTCGGAGATTCG; TNF-a, Forward primer: TGCACTTTGGAGTGATCGGC, Reverse primer: ACTCGGGGTTCGAGAAGATG; GAPDH, Forward primer: AGGTCGGTGTGAACGGATTTC, Reverse primer: TGTAGACCATGTAGTTGAGGTCA. Western blot analysis BEAS-2B cells were homogenized in RIPA lysis buffer (CWBIO, China) containing protease inhibitors to extract total proteins. Following centrifugation, protein concentration was determined using a BCA protein assay kit (Solarbio, China). Equal amounts of protein were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene fluoride (PVDF) membranes. Membranes were incubated overnight at 4℃ with primary antibodies. The primary antibodies were as follows: EGFR Monoclonal antibody (Cat#66455-1-Ig, 1:10000, Proteintech, USA), PI3K antibody (Cat#67121-1-Ig, 1:5000, Proteintech, USA), P-PI3K antibody (Cat#Bs-6417R,1:1000, China), STAT3 antibody (Cat# ab109085, 1:2000, Abcam, UK), p-STAT3 antibody (Cat#ab267373, 1:2000, Abcam, UK), AKT antibody (Cat#10176-2-AP, 1:2000, Proteintech, USA), P-AKT (Cat# 66444-1-Ig, 1:1000, Proteintech, USA), β-ACTIN antibody(Cat#20536-1-AP, 1:10000, Proteintech, USA). After washing, membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies. Finally, protein bands were visualized using a fully automatic gel imaging analysis system. After protein transfer, the PVDF membranes were cut into strips according to the molecular weight of the target proteins prior to antibody hybridization. Statistical analysis GraphPad Prism software 9.0 (GraphPad Prism; San Diego, CA, USA) was used for data analysis. All data were expressed as mean± standard deviation(SD). One-way analysis of variance (ANOVA) was employed for multiple group comparisons, followed by Tukey’s post-hoc test to identify significant differences between groups. A P-value < 0.05 was considered statistically significant. Results Screening of potential targets for GS Rg1 and COPD A total of 159 target genes of GS Rg1 were identified from the HERB database, Swiss Target Prediction platform, and GeneCards database after removing duplicate entries (Fig. 1A). For COPD-related disease targets, 4716 genes were retrieved from the GeneCards, MalaCards, and OMIM databases, followed by the elimination of duplicates (Fig. 1B). A Venn diagram was constructed using the Venny platform to visualize the overlapping targets between GS Rg1 and COPD (Fig. 1C), revealing that 144 gene targets may be involved in the regulatory effects of GS Rg1 on COPD (Fig. 1C). PPI network analysis The STRING database was employed to analyze the PPI network of the overlapping targets, yielding a network consisting of 144 nodes and 2519 edges (Figure S1). The resulting data were then imported into Cytoscape v3.10.3 software to construct a PPI network diagram of overlapping targets between COPD and GS Rg1 (Figure S2). Nodes with darker colors and greater color contrast between nodes and edges indicate stronger PPI. Additionally, the color gradient of each node reflects its interaction degree: the lighter the node color from the inside out, the weaker the protein-protein interaction. Eight genes exhibiting higher values of “Degree”, “Betweenness Centrality”, and “Closeness Centrality” (exceeding twice the median value) were identified as the core targets of GS Rg1 in the preventing COPD, namely AKT1, TNF, TP53, STAT3, CASP3, EGFR, CTNNB1, and SRC (Fig. 1D). GO and KEGG functional enrichment analysis To elucidate the functional and pharmacological mechanisms of GS Rg1 in treating COPD, the overlapping targets were subjected to enrichment analysis using the DAVID database. Based on the criterion of P < 0.05, 150 biological functions were identified, including 113 biological processes (BP), 18 cellular components (CC), and 19 molecular functions (MF). The top 10 significantly enriched categories in BP, CC, and MF were sorted in ascending order of P-value and visualized (Fig. 2A). The analysis showed that BP mainly included functions related to the apoptotic process, regulation of MAPK signaling cascades, response to the TGFB receptor signaling pathway, and response to inflammatory stimuli. CC primarily involved components such as protein-containing complexes, the plasma membrane, and cell-cell junctions, while MF mainly focused on protein phosphatase binding, kinase binding, protease binding, and signaling receptor binding. These findings indicate that GS Rg1 exerts its intervention effect on COPD through multiple pathways and mechanisms. In the KEGG enrichment analysis, 80 related signaling pathways were obtained, mainly involving the mitogen-activated protein kinase (MAPK) signaling pathway and PI3K/Akt signaling pathway. A histogram of the top 10 KEGG-enriched pathways (P < 0.05) is shown in Fig. 2B. These 10 KEGG-enriched pathways were further visualized using Omicshare (http://www.omicshare.com/) to generate a bubble chart (Fig. 2C), where pathways are arranged in ascending order of P-value. The size of each bubble corresponds to the number of enriched targets, and the color of the bubble indicates the magnitude of the P-value. Molecular docking The Cavity-Detection Guided Blind Docking Tools (http://183.56.231.194: 8001/cb-dock2/index.php) was used to perform molecular docking between the active component (ginsenoside Rg1) and the eight core targets (Fig. 3A). A binding energy of less than 0 kcal/mol indicates spontaneous binding between the ligand and receptor; the lower the binding energy, the more stable the binding conformation and the higher the likelihood of interaction. Generally, a binding energy less than − 5.0 kcal/mol suggests good binding activity between a small-molecule ligand and a receptor protein30. The optimal docking results were selected for visual analysis of molecular docking (Fig. 3B), where dotted lines represent hydrogen bonds and the values indicate bond lengths. The results demonstrated that ginsenoside Rg1 exhibited the strongest binding activity. Visualization of molecular docking. (A) Binding energy of molecular docking. (B) Diagram of molecular docking. Molecular docking results indicated that GS Rg1 formed strong interactions with all eight core target proteins (AKT1, TNF, TP53, STAT3, CASP3, EGFR, CTNNB1, and SRC) (Fig. 3A). The binding affinities of these proteins with GS Rg1 were all less than − 5.9 kcal/mol, suggesting effective binding between GS Rg1 and these core targets. The binding energies of GS Rg1 with each core target are summarized in Fig. 3A. Protection effect of ginsenoside Rg1 on LPS- and CSE- stimulated BEAS-2B cells The cytotoxicity of GS Rg1 at concentrations ranging from 1 to 50µM was evaluated using the CCK-8 assay. The results showed no significant cytotoxicity within the concentration range of 1–50µM (Fig. 4A). The protective effect of GS Rg1 against CSE/LPS-induced cytotoxicity in BEAS-2B cells was measured by the CCK-8 assay, which demonstrated that GS Rg1 at concentrations of 10–50µM reversed CSE/LPS-induced cellular damage (Fig. 4B). Therefore, 10µM GS Rg1 was selected for subsequent intervention experiments. GS Rg1 ameliorates inflammation and oxidative stress in BEAS-2B cells. (A) Cell viability exposure to different concentrations of GS Rg1 determined by CCK-8 assay. (B) After exposing BEAS-2B cells to CSE/LPS, Cell viability exposure to different concentrations of GS Rg1 determined by CCK-8 assay. Data are presented as mean ± SD(n = 6). *P < 0.5, ****P < 0.0001. (C) IL-1β, IL-6 and TNF-α mRNA levels in BEAS-2B cells. (D) IL-1β content was quantitative by ELISA assay. (E) IL-6 content was quantitative by ELISA assay. (F) TNF-α content was quantitative by ELISA assay. (G) ROS content was quantitative by ROS kit assay. (H) MDA content was quantitative by MDA kit assay. (I) SOD content was quantitative by SOD kit assay. (J) CAT content was quantitative by CAT kit assay. Data are presented as mean ± SD(n = 6). ****P < 0.0001. In addition, cell damage models were established to comprehensively simulate epithelial cell damage in COPD. In BEAS-2B cells stimulated with CSE/LPS, the levels and mRNA levels of IL-1β, IL-6, and TNF-α (Fig. 4C) were significantly increased, while GS Rg1 treatment reduced the expression of these pro-inflammatory cytokines (Fig. 4C). Similarly, the trends in the expression levels of these inflammatory factors were also reflected by the ELISA assay (Fig. 4D-F). Furthermore, GS Rg1 decreased the levels of ROS(Fig. 4G) and MDA(Fig. 4H), while increasing the activities of SOD(Fig. 4I) and CAT (Fig. 4J). Effects of GS Rg1 on the EGFR signaling pathway Our network pharmacological analysis yielded important insights into Epidermal Growth Factor Receptor (EGFR), which serves as an upstream target of the phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) signaling pathway. Experimental validation confirmed that CSE significantly upregulated EGFR expression in BEAS-2B cells, whereas GS Rg1 treatment markedly decreased EGFR expression levels (Fig. 5A and B). Furthermore, CSE exposure significantly increased the phosphorylation levels of PI3K and AKT in BEAS-2B cells. In contrast, GS Rg1 effectively reversed the elevated phosphorylation of AKT and exhibited a trend toward reducing PI3K phosphorylation (Fig. 5C and F). STAT3, a crucial inflammatory regulator, is an essential downstream signaling molecule of EGFR. To assess the potential effect of GS Rg1 on STAT3, we conducted an analysis of the STAT3 expression and phosphorylation levels and found that CSE could significantly increase the levels of phosphorylated STAT3 and STAT3. Conversely, GS Rg1 was found to markedly reduce the expression of p-STAT3 (Fig. 5G and H). Therefore, GS Rg1 appears to ameliorate inflammation through the inhibition of the EGFR/STAT3 signal pathway. The protective mechanism of GS Rg1 on COPD through inhibiting EGFR. (A) Representative western blot images of EGFR. (B) quantitative analysis data of EGFR (mean ± SD, n = 3, *P < 0.05, ***P < 0.001) are shown. (C) Representative western blot images of p-AKT. (D) quantitative analysis data of p-AKT (mean ± SD, n = 3, **P < 0.01, ***P < 0.001) are shown. (E) Representative western blot images of p-PI3K. (F) quantitative analysis data of p-PI3K (mean ± SD, n = 3, *P < 0.05) are shown. (G) Representative western blot images of p-STAT3. (H) quantitative analysis data of p-STAT3 (mean ± SD, n = 3, *P < 0.05, **P < 0.01) are shown. All original blot bands are provided in the supplementary Figure S3. Discussion In the present study, network pharmacology was employed to explore the therapeutic targets of GS Rg1 in the treatment of COPD. Subsequently, molecular docking was utilized to investigate the binding affinity between GS Rg1 and these targets. Finally, an in vitro COPD model was established to validate the primary pharmacodynamic mechanism of GS Rg1 in treating COPD. This integrated research strategy provides valuable guidance and insights for investigating the pharmacodynamic basis and mechanism of GS Rg1, as well as for studies on other Traditional Chinese Medicines (TCMs). Current therapeutic approaches for COPD only relieve restricted airflow without reversing the decline in lung function. Common COPD medications, such as bronchodilators and glucocorticoids, often exert significant side effects. In contrast, TCM has demonstrated positive efficacy in COPD treatment; for instance, YuPingFeng Granules31, JianPiYiFei II Granules32, and BuFei YiShen Granules33 have all shown remarkable therapeutic effects in clinical practice. Furthermore, TCM offers unique theories and methods for treating COPD, emerging as an important research direction for the effective management of this condition. A key pathological feature of COPD is chronic inflammation of the lung parenchyma and pulmonary vasculature, accompanied by infiltration of various immune cells and excessive production of inflammatory cytokines. These pathological changes, in turn, damage lung structure and recruit more inflammatory immune cells34. In this study, GS Rg1 was found to protect epithelial cells and reduce mucin synthesis and secretion. Additionally, GS Rg1 downregulated the expression of proinflammatory cytokines (including IL-1β, IL-6, TNF-α, and IL-13) and factors associated with mucus hypersecretion (MUC5ac), indicating that it may inhibit lung damage through anti-inflammatory pathways. In the network pharmacology analysis, PPI network analysis identified three targets with the highest scores, namely EGFR, PI3K, and AKT, which are the most promising targets contributing to the therapeutic effect of GS Rg1 in COPD. Inflammatory responses increase the levels of EGFR and its ligands; high expression and positive activation of EGFR promote the proliferation of airway epithelial goblet cells and mucus production. Moreover, cigarette smoke activates neutrophils, leading to overexpression of EGFR in airway epithelial cells and stimulation of mucin synthesis35. As a downstream pathway of EGFR, the PI3K/AKT signaling pathway is a key regulator of inflammation and airway remodeling in COPD36. Furthermore, KEGG pathway enrichment analysis predicted that the PI3K/AKT signaling pathway (hsa04151) plays the most critical role in the intervention of COPD by GS Rg1, which is consistent with the results of PPI network analysis. In further predictive analysis, molecular docking was used to predict the binding between GS Rg1 and key targets. Interestingly, GS Rg1 exhibited strong binding capacity with the key targets. Of course, it cannot be completely confirmed that these bindings have therapeutic effects, as the activation or inhibition of the targets by these bindings remains unknown. However, this positive result provides inspiration for further exploration. In the current landscape of drug research, cutting-edge computer technologies such as network pharmacology37 and molecular docking38 are revolutionizing the field. These innovative tools provide efficient and reliable methods for high-throughput analysis, driving the search for new breakthroughs in pharmaceutical development. EGFR is a complex receptor composed of four types of cell surface receptors39. In addition, EGFR has thirteen extracellular ligands and four important downstream effector pathways, including the MEK/ERK, PI3K/AKT, STAT, and mTOR pathways, which regulate a wide range of cellular functions40–43. Aberrant activation of EGFR promotes excessive airway proliferation, neutrophil recruitment, and mucus overproduction and hypersecretion44. The finding that GS Rg1 downregulated EGFR expression suggests that GS Rg1 may act as an effective antagonist of EGFR signaling, minimizing adverse effects while preserving normal respiratory function. Beyond the mechanism predicted by network pharmacology, we found that GS Rg1 can reduce inflammation by decreasing the phosphorylation level of STAT3. STAT3 is another member of the STAT transcription factor family45 and can also be activated by IL-1346,47. The results showed that GS Rg1 inhibits the phosphorylation of STAT3, thereby contributing to the improvement of COPD. This finding expands our understanding of the mechanism by which GS Rg1 ameliorates COPD. Furthermore, it reminds us of the multifaceted nature of TCM research, which is characterized by multi-component, multi-target, and multi-link approaches. Although network pharmacology provides a more targeted framework, it may inadvertently limit the comprehensive exploration of the pharmacodynamic mechanisms inherent in TCM in certain aspects. In addition, a concrete and intuitive visualized mechanism diagram illustrating the intervention of GS Rg1 in COPD is presented in Fig. 6. A concrete and intuitive visualized mechanism diagram illustrating the intervention of GS Rg1 in COPD. Conclusion GS Rg1 exerts a significant ameliorative effect on COPD by mitigating inflammatory responses and suppressing mucus hypersecretion. The potential mechanism underlying this therapeutic effect is hypothesized to involve the inhibition of the EGFR/PI3K/AKT and EGFR/STAT3 signaling pathways. Our results clarify the pathogenic mechanisms of COPD induced by CSE/LPS and add to the growing body of evidence supporting GS Rg1 as a promising candidate for the therapeutic intervention of COPD. Limitation Several limitations of this study should be taken into consideration. As a pleiotropic compound, ginsenoside Rg1 regulates multiple targets and signaling pathways. While our study focused specifically on the EGFR/PI3K/AKT and EGFR/STAT3 signaling pathways, other potential regulatory mechanisms remain uninvestigated. Additionally, the current findings are insufficient to definitively determine whether the EGFR/PI3K/AKT and EGFR/STAT3 signaling pathways act as primary direct targets of GS Rg1 or as downstream nodes of other regulatory pathways. Future research should incorporate more comprehensive mechanistic investigations to fully clarify the protective mechanisms of GS Rg1 in COPD. Moreover, the BEAS-2B CSE/LPS model employed in this study is a simplified in vitro system that predominantly mimics acute epithelial inflammation and injury. It does not fully reflect the chronic, progressive, and multicellular nature of COPD, including processes such as emphysema, small airway remodeling, and long-term inflammatory cell infiltration. Therefore, our findings primarily illustrate the acute protective effects of GS Rg1 on airway epithelial cells. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Abbreviations Chronic obstructive pulmonary disease Lipopolysaccharide Gene ontology Kyoto encyclopedia of genes and genomes Molecular function Protein-protein interaction Ginsenoside Rg1 Mitogen-activated protein kinases Nuclear factor-κB Author contributions L.X. and J.X. wrote the main manuscript text and X.L., D.X., L.H., L.L. G. W. prepared figures 1-6. All authors reviewed the manuscript.” Data availability If you have data from this study, please contact the corresponding author (Jing Xu) by email. Declarations Competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement If you have data from this study, please contact the corresponding author (Jing Xu) by email.